A meta-analysis including EMPA-REG OUTCOME (empagliflozin), CANVAS Program (canagliflozin), DECLARE-TIMI 58 (dapagliflozin), CREDENCE (canagliflozin) and VERTIS CV (ertugliflozin) demonstrated that SGLT2 inhibitors reduced MACE by 10% (hazard ratio [HR] 0.90, 95% confidence interval [CI] 0.850.95) and hospitalization for heart failure by 32% (HR 0.68, 95% CI 0.610.76) compared to placebo [6]
Renal allograft fibrosis: biology and therapeutic targets
Women who use birth control and start tirzepatide should talk to their doctor about the best type of contraception for their needs
Fabrication of silk fibroin nanoparticles for controlled drug delivery
Related Stories Genetic variants may help explain who loses more weight and who gets side effects on GLP-1 drugs GLP-1 users say the drugs quiet food noise but do not replace lifestyle change GLP-1 weight-loss drugs may also reduce binge eating Behavioral outcomes included substance intake, operant motivation, relapse-like reinstatement, and drug-seeking behavior
Multiple formulation-related variants may also appear during analysis
